OncoSec Medical (OncoSec Medical) FCF Yield % : 0.00 (As of May. 12, 2024)

View and export this data going back to 1986. Start your Free Trial

What is OncoSec Medical FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, OncoSec Medical's Trailing 12-Month Free Cash Flow is $-25.00 Mil, and Market Cap is $0.00 Mil. Therefore, OncoSec Medical's FCF Yield % for today is 0.00%.

The historical rank and industry rank for OncoSec Medical's FCF Yield % or its related term are showing as below:

ONCSQ's FCF Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: -14.17
* Ranked among companies with meaningful FCF Yield % only.

OncoSec Medical's FCF Margin % for the quarter that ended in Jan. 2023 was 0.00%.

OncoSec Medical FCF Yield % Historical Data

The historical data trend for OncoSec Medical's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical FCF Yield % Chart

OncoSec Medical Annual Data

Trend

Jul13

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

FCF Yield %

Get a 7-Day Free Trial

-35.10

-122.36

-34.23

-49.90

-114.18

OncoSec Medical Quarterly Data
	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23
FCF Yield %	Get a 7-Day Free Trial															-109.44	-63.87	-97.54	-148.12	-404.55

Competitive Comparison of OncoSec Medical's FCF Yield %

For the Biotechnology subindustry, OncoSec Medical's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoSec Medical's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's FCF Yield % distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's FCF Yield % falls into.

OncoSec Medical FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

OncoSec Medical's FCF Yield % for the fiscal year that ended in Jul. 2022 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-32.383	/	28.36226822
	=	-114.18%

OncoSec Medical's annualized FCF Yield % for the quarter that ended in Jan. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-6.611	*	4	/	6.53664
	=	-404.55%

OncoSec Medical FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

OncoSec Medical FCF Yield % Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoSec Medical (OncoSec Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (OTCPK:ONCSQ) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

24 North Main Street, Pennington, NJ, USA, 08534

Website

https://www.oncosec.com

OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

Executives

Robert J Delaversano	officer: Principal Accounting Officer	217 W. MAIN STREET, SOMERVILLE NJ 08876
Spahr Stephany Foster	director	C/O ONCOSEC MEDICAL, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Robert H. Arch	officer: President and CEO	C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
George Chi	officer: Chief Financial Officer	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Lin Shi	director	24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218
Margaret Dalesandro	director	ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Yuhang Zhao	director	6 HORTON DR., CHESTER NJ 07930
Brian A Leuthner	officer: Chief Operating Officer	200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Daniel J. O'connor	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
China Grand Pharmaceutical & Healthcare Holdings Ltd	10 percent owner, other: See Remarks	UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000
Alpha Holdings, Inc.	director, 10 percent owner	GANGNAM-GU APGUJEONG-RO 62-GIL 17-10, SEOUL M5 06016
Kellie Malloy Foerter	officer: Chief Operating Officer	C/O ONCOSEC MEDICAL INCORPORATED, 24 N. MAIN STREET, PENNINGTON NJ 08534-2218
Herbert Kim Lyerly	director	C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218
Chao Zhou	director	UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000
Grand Decade Developments Ltd	10 percent owner, other: See Remarks	UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000